Tag
This article reviews evidence supporting OCT measurements of retinal layers as biomarkers for predicting multiple sclerosis progression and highlights the need for further research to enhance clinical application.
This review synthesizes evidence demonstrating that continuous glucose monitoring (CGM) metrics, particularly time above 140 mg/dL, predict progression to stage 3 type 1 diabetes with accuracy comparable to oral glucose tolerance test (OGTT
Iatrogenic cerebral amyloid angiopathy (iCAA) exhibits high symptomatic intracerebral hemorrhage rates decades after exposure. This analysis of 82 European cases highlights recurrence risks and cognitive outcomes, informing prognosis and pa
Monitoring chronic pulmonary aspergillosis progression using time-normalized anti-Aspergillus IgG kinetics shows promise for early detection of disease worsening, supporting timely clinical reassessment alongside imaging and microbiology.
This study links MC1R loss-of-function variants to faster motor decline and phenoconversion in Parkinson’s disease, suggesting their value for prognosis and clinical trial design in European descent patients.
This review synthesizes recent evidence on event-based progression detection in glaucoma, highlighting that OCTA vessel density may identify progression earlier than structural OCT or visual field testing, with important implications for cl
A stress test measuring intraocular pressure identifies glaucoma patients at risk of rapid progression despite normal office pressure readings, offering complementary prognostic insights beyond routine checks.
This study identifies three candidate geographic atrophy phenotypes in age-related macular degeneration, revealing distinct growth rates and severity, with implications for prognosis and clinical trials.
This article explores a novel, biologically informed framework for monitoring transthyretin amyloid cardiomyopathy progression and treatment, emphasizing mechanism-specific strategies aimed at personalized care.
This article presents the PRISM model, a unified glaucoma classification integrating risk profiling, structural imaging, functional testing, and disease progression to enhance diagnosis and inform treatment strategies for open-angle glaucom
Serum GFAP elevation predicts progression independent of relapse in MS; therapy-induced GFAP reduction associates with decreased progression risk, supporting GFAP as a biomarker for progression risk stratification and treatment monitoring.
Two immunologically distinct, age-independent subtypes of new-onset type 1 diabetes demonstrate differing progression rates and therapeutic responses, offering a path toward tailored immunotherapies.
This study assesses the added value of 10-2 visual field testing compared to the 24-2 test in detecting progression of early glaucoma, highlighting its role in patients with localized central visual field loss.
A landmark study identifies a decade-long conserved sequence of disease progression in IPF, revealing that DLCO decline precedes FVC impairment by years, providing a new framework for early diagnosis and clinical trial design.
This review analyzes how age at onset influences NMOSD, revealing that while relapse risk remains constant across age groups, older onset significantly accelerates disability progression, necessitating early high-efficacy therapy.
This article explores how genomic features differentiate stable from progressive asymptomatic Waldenström macroglobulinemia and IgM-MGUS, highlighting mutation burdens, specific gene alterations, and aneuploidy as prognostic markers for dis
This 5-year prospective cohort study reveals that high-dose statin therapy significantly slows abdominal aortic aneurysm growth and reduces the risks of repair, rupture, and death in men, suggesting benefits beyond traditional cardiovascula
